Clinical trials for preventing post stroke cognitive impairment
- PMID: 20855090
- DOI: 10.1016/j.jns.2010.08.052
Clinical trials for preventing post stroke cognitive impairment
Abstract
Post stroke dementia (PSD) develops in up to 40% of patients and often co-exists with Alzheimer's disease in the elderly. Unsurprisingly, the combination of stroke and dementia is associated with considerable morbidity and mortality, and is devastating to patients and carers. Limited trial evidence suggests that lowering high blood pressure reduces the development of cognitive decline, vascular dementia and PSD, although whether this relates to the magnitude of BP reduction or specific drug classes remains unclear. Biological plausibility and/or existing studies suggest that other types of drug treatments might also be effective, including choline esterase inhibitors, lipid lowering agents, antiplatelet agents, and selective serotonin reuptake inhibitors. Preventing cognitive decline and dementia post stroke is critical and large definitive trials are now needed.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
From neuronal and vascular impairment to dementia.Pharmacopsychiatry. 1999 Mar;32 Suppl 1:17-24. doi: 10.1055/s-2007-979232. Pharmacopsychiatry. 1999. PMID: 10338104 Review.
-
[Cognitive functions and hypertension].Arch Mal Coeur Vaiss. 2005 Feb;98(2):133-9. Arch Mal Coeur Vaiss. 2005. PMID: 15787305 Review. French.
-
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.Pharmacotherapy. 2008 Mar;28(3):366-75. doi: 10.1592/phco.28.3.366. Pharmacotherapy. 2008. PMID: 18294116 Review.
-
[Hypertension in the elderly and risk of dementia].Rev Prat. 2010 May 20;60(5):649-53. Rev Prat. 2010. PMID: 20564847 French.
-
Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials.Ann N Y Acad Sci. 2010 Oct;1207:155-62. doi: 10.1111/j.1749-6632.2010.05726.x. Ann N Y Acad Sci. 2010. PMID: 20955439 Review.
Cited by
-
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.Stroke. 2017 May;48(5):1262-1270. doi: 10.1161/STROKEAHA.116.014321. Stroke. 2017. PMID: 28432265 Free PMC article. Clinical Trial.
-
Development and validation of a risk score (CHANGE) for cognitive impairment after ischemic stroke.Sci Rep. 2017 Sep 29;7(1):12441. doi: 10.1038/s41598-017-12755-z. Sci Rep. 2017. PMID: 28963553 Free PMC article.
-
Automatic Artifact Removal in EEG of Normal and Demented Individuals Using ICA-WT during Working Memory Tasks.Sensors (Basel). 2017 Jun 8;17(6):1326. doi: 10.3390/s17061326. Sensors (Basel). 2017. PMID: 28594352 Free PMC article.
-
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline.Mol Neurodegener. 2021 Feb 15;16(1):7. doi: 10.1186/s13024-020-00421-4. Mol Neurodegener. 2021. PMID: 33588894 Free PMC article.
-
Hypertension and Its Impact on Stroke Recovery: From a Vascular to a Parenchymal Overview.Neural Plast. 2019 Oct 14;2019:6843895. doi: 10.1155/2019/6843895. eCollection 2019. Neural Plast. 2019. PMID: 31737062 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical